Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Oct 8, 2014 at 10:30 AM EDT

AutoGenomics Files for IPO — Sorry, Files Again

AutoGenomics has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.

Chris Lange | Oct 7, 2014 at 9:20 AM EDT

INC Research Files for IPO

INC Research Holdings Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.

Chris Lange | Oct 6, 2014 at 2:05 PM EDT

Reality Sets in for Ebola Drug Hopefuls

Tekmira Pharmaceuticals downgrade also drags down Sarepta Therapeutics and BioCryst Pharmaceuticals.

Chris Lange | Oct 6, 2014 at 11:50 AM EDT

Alcobra Loses Focus in ADHD Trial for FDA Approval

Alcobra recently posted news of an FDA trial and its shares traded down about 50% Monday morning.

Jon C. Ogg | Oct 6, 2014 at 10:15 AM EDT

Chimerix Wants Its Piece of the Ebola Pie

Chimerix has announced that its lead drug candidate has been provided for potential use in patients with Ebola virus disease.

Jon C. Ogg | Oct 2, 2014 at 12:40 PM EDT

Analyst Still Sees Zogenix Potentially Doubling

Oppenheimer's official rating on Zogenix remains Outperform, but what stands out is that the $2.50 price target implies that shares…

Lee Jackson | Oct 2, 2014 at 8:55 AM EDT

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.

Chris Lange | Oct 1, 2014 at 10:35 AM EDT

Biotech Company FibroGen Files for IPO

Biotech company FibroGen filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.

Jon C. Ogg | Oct 1, 2014 at 9:55 AM EDT

Major Fallout Stocks After Confirmed Ebola Case in United States

With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides…

Jon C. Ogg | Sep 30, 2014 at 5:16 PM EDT

Reaction to Confirmed Ebola Case in U.S. — UPDATED

News has hit of the first confirmed Ebola case in the United States. Companies involved in potential drugs for Ebola…

Chris Lange | Sep 30, 2014 at 4:18 PM EDT

What Else Is Under the Hood for Catalyst Pharma?

ThinkstockCatalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its Phase 3 clinical trial of Firdapse for the…

Chris Lange | Sep 29, 2014 at 1:45 PM EDT

Is Ambit Biosciences Getting Enough in Its Buyout?

Ambit Biosciences has announced that it is entering into a merger with Daiichi Sankyo in a deal worth up to…

Jon C. Ogg | Sep 29, 2014 at 1:10 PM EDT

Can Repros Therapeutics Shares Still More Than Double?

What do you do when an analyst report comes out that maintains a price target position that implies shares can…

Chris Lange | Sep 29, 2014 at 10:55 AM EDT

Will Analysts Start Following Alimera After Its FDA Approval?

Alimera Sciences traded up big on Monday on news that the company received FDA approval for its diabetic macular edema…

Lee Jackson | Sep 29, 2014 at 8:30 AM EDT

3 Likely Biotech Buyout Candidates

A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could…

1 … 279 280 281 282 283 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

AutoGenomics Files for IPO — Sorry, Files Again

INC Research Files for IPO

Reality Sets in for Ebola Drug Hopefuls

Alcobra Loses Focus in ADHD Trial for FDA Approval

Chimerix Wants Its Piece of the Ebola Pie

Analyst Still Sees Zogenix Potentially Doubling

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

Biotech Company FibroGen Files for IPO

Major Fallout Stocks After Confirmed Ebola Case in United States

Reaction to Confirmed Ebola Case in U.S. — UPDATED

What Else Is Under the Hood for Catalyst Pharma?

Is Ambit Biosciences Getting Enough in Its Buyout?

Can Repros Therapeutics Shares Still More Than Double?

Will Analysts Start Following Alimera After Its FDA Approval?

3 Likely Biotech Buyout Candidates

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Morgan Stanley Lifts IonQ Price Target to $47: Is the Quantum Computing Stock Finally Ready to Deliver?

Market Greed Is Back: Oil and the Hormuz Strait Didn’t Get the Memo.

Big Oil Has Transformed Into Shareholder-Friendly Cash Machines, Says CNBC’s Halftime Report

Social Security Cuts Inch Closer to Reality as Lawmakers Weigh Options

A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss

Oppenheimer Upgrades Airbnb to Outperform With $180 Price Target: Are Hotels and the World Cup About to Re-Rate the Stock?

AMD Will Be a $1 Trillion Company Faster Than You Think

Health and Healthcare Articles

All Health and Healthcare Articles

AutoGenomics Files for IPO — Sorry, Files Again

INC Research Files for IPO

Reality Sets in for Ebola Drug Hopefuls

Alcobra Loses Focus in ADHD Trial for FDA Approval

Chimerix Wants Its Piece of the Ebola Pie

Analyst Still Sees Zogenix Potentially Doubling

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

Biotech Company FibroGen Files for IPO

Major Fallout Stocks After Confirmed Ebola Case in United States

Reaction to Confirmed Ebola Case in U.S. — UPDATED

What Else Is Under the Hood for Catalyst Pharma?

Is Ambit Biosciences Getting Enough in Its Buyout?

Can Repros Therapeutics Shares Still More Than Double?

Will Analysts Start Following Alimera After Its FDA Approval?

3 Likely Biotech Buyout Candidates

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Morgan Stanley Lifts IonQ Price Target to $47: Is the Quantum Computing Stock Finally Ready to Deliver?

Market Greed Is Back: Oil and the Hormuz Strait Didn’t Get the Memo.

Big Oil Has Transformed Into Shareholder-Friendly Cash Machines, Says CNBC’s Halftime Report

Featured Reads

Social Security Cuts Inch Closer to Reality as Lawmakers Weigh Options

A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss